Amneal Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference

BRIDGEWATER, N.J., Dec. 19, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that members of management will present at the 37^th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis in San Francisco on Tuesday, January 8, 2019.

Rob Stewart, President and CEO of Amneal will present the presentation at 8:30 AM Pacific Time (11:30 AM Eastern Time). To access a live webcast of the presentation, visit Amneal's Investor Relations Web site at https://investors.amneal.com. The webcast can also be accessed at the following URL:

https://jpmorgan.metameetings.net/events/healthcare19/sessions/23899-amneal-pharmaceuticals/webcast 

Following the presentation, Paul Bisaro, Executive Chairman of Amneal, and Bryan Reasons, Senior Vice President and Chief Financial Officer of Amneal, will join Mr. Stewart for a Q&A sessions at 9:00 AM Pacific Time (12:00 PM Eastern Time). To access a live webcast of the Q&A session, visit Amneal's Investor Relations Web site at https://investors.amneal.com. The webcast can also be accessed at the following URL:

https://jpmorgan.metameetings.net/events/healthcare19/sessions/24235-amneal-pharmaceuticals-q-a/webcast 

An archived version will be available approximately one hour after the live presentation and Q&A session ends and can be accessed at the same locations for 90 days.

About Amneal
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is an integrated pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company has approximately 6,500 employees in its operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the United States.

Amneal is one of the largest and fastest growing generic pharmaceutical manufacturers in the United States, with an expanding portfolio of generic products to include complex dosage forms in a broad range of therapeutic areas. The Company also markets a portfolio of branded pharmaceutical products through its Specialty Pharma division focused principally on central nervous system disorders and parasitic infections. For more information, visit www.amneal.com.

CONTACT:
Mark Donohue
(908) 409-6718        

SOURCE Amneal Pharmaceuticals, Inc.

Related Links

http://www.amneal.com